<DOC>
	<DOCNO>NCT01798914</DOCNO>
	<brief_summary>The purpose study allow patient specific need inhaled insulin continue inhale insulin therapy use Technosphere Insulin Exubera withdrawn market .</brief_summary>
	<brief_title>Patient Transitioning From Exubera® Inhalation Powder Technosphere® Insulin Inhalation Powder</brief_title>
	<detailed_description>A Phase 3 , open label , multicenter , safety follow trial convert treatment subject currently use Exubera treatment TI Inhalation Powder</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Respiratory Aspiration</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>Subject type 1 type 2 diabetes mellitus currently treat treat Exubera . Subject severe phobia sc injection insulin ( needle phobia ) prevent conventional treatment OR impair sc insulin absorption Smoking previous 6 month History asthma chronic obstructive pulmonary disease ( COPD ) significant pulmonary disease , exposure pulmonary toxin . Clinically significant pulmonary abnormality chest highresolution compute tomography ( HRCT ) . PFT result prior transfer TI Inhalation Powder show follow : FEV1 &lt; 70 % predict , FVC &lt; 70 % predict , DLCO &lt; 70 % predict , TLC &lt; 80 % predict . Allergy insulin</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>